

# Medical anti-glaucoma therapy: Beyond the drop

Veterinary Ophthalmology

24, 2-15

DOI: [10.1111/vop.12843](https://doi.org/10.1111/vop.12843)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Looking into the future: Gene and cell therapies for glaucoma. <i>Veterinary Ophthalmology</i> , 2021, 24, 16-33.	1.0	20
2	Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients. <i>Journal of Ophthalmology</i> , 2021, 2021, 1-12.	1.3	3
3	Progress in drug formulation design and delivery of medicinal substances used in ophthalmology. <i>International Journal of Pharmaceutics</i> , 2021, 607, 121012.	5.2	14
4	Ocular Neurodegenerative Diseases: Interconnection between Retina and Cortical Areas. <i>Cells</i> , 2021, 10, 2394.	4.1	55
5	Medical therapy for glaucoma: A review. <i>Clinical and Experimental Ophthalmology</i> , 2022, 50, 198-212.	2.6	26
6	Testing drug release from medicated contact lenses: The missing link to predict in vivo performance. <i>Journal of Controlled Release</i> , 2022, 343, 672-702.	9.9	21
7	Ocular Surface Disease in Glaucoma Patients. <i>Current Eye Research</i> , 2023, 48, 219-230.	1.5	2
8	Intravitreal Injectable Hydrogels for Sustained Drug Delivery in Glaucoma Treatment and Therapy. <i>Polymers</i> , 2022, 14, 2359.	4.5	9
9	TYRP1 Protects Against the Apoptosis and Oxidative Stress of Retinal Ganglion Cells by Binding to PMEL. <i>Ocular Immunology and Inflammation</i> , 0, , 1-11.	1.8	2
10	Recent Strategies for Ocular Drug Delivery: Promises and Challenges. , 0, , .		0
11	Intravitreal Systems For Targeted Drug Delivery To The Posterior Eye Segment: A Systematic Review. <i>Russian Open Medical Journal</i> , 2022, 11, .	0.3	0
12	How study of naturally occurring ocular disease in animals improves ocular health globally. <i>Journal of the American Veterinary Medical Association</i> , 2022, 260, 1887-1893.	0.5	0
13	A Review on Polymeric Nanostructured Micelles for the Ocular Inflammation-Main Emphasis on Uveitis. <i>Pharmaceutical Nanotechnology</i> , 2023, 11, 34-43.	1.5	3
14	3D-printed long-acting 5-fluorouracil implant to prevent conjunctival fibrosis in glaucoma. <i>Journal of Pharmacy and Pharmacology</i> , 2023, 75, 276-286.	2.4	2
15	The Antibiotic Kitasamycinâ€”A Potential Agent for Specific Fibrosis Preventing Therapy after Fistulating Glaucoma Surgery?. <i>Pharmaceutics</i> , 2023, 15, 329.	4.5	0
16	Intracameral Drug Delivery: A Review of Agents, Indications, and Outcomes. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2023, 39, 102-116.	1.4	6
17	Heritable Risk and Protective Genetic Components of Glaucoma Medication Non-Adherence. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5636.	4.1	2
18	Investigation of the Relationship Between Chronic Use of Topical Antiglaucomatous Drops and Ocular Demodex Infestation. <i>Journal of Contemporary Medicine</i> , 2023, 13, 225-228.	0.2	0

#	ARTICLE	IF	CITATIONS
19	iDose TR Sustained-release Travoprost Implant for the Treatment of Glaucoma. , 2023, 17, 4.		1
20	Glaucoma: Novel antifibrotic therapeutics for the trabecular meshwork. European Journal of Pharmacology, 2023, 954, 175882.	3.5	2
21	Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies. Journal of Clinical Medicine, 2023, 12, 5798.	2.4	1
22	Understanding the complex genetics and molecular mechanisms underlying glaucoma. Molecular Aspects of Medicine, 2023, 94, 101220.	6.4	0
23	Long-Acting Ocular Injectables: Are We Looking In The Right Direction?. Advanced Science, 2024, 11, .	11.2	0
24	Future directions of glaucoma treatment: emerging gene, neuroprotection, nanomedicine, stem cell, and vascular therapies. Current Opinion in Ophthalmology, 2024, 35, 89-96.	2.9	0